2020/4/8

何不試試用數位電子製藥技術開發和量產疫苗和藥物 Why not try to use digital electronic pharmaceutical technology to develop and mass produce vaccines and drugs


據報導世界各地的醫生和研究團隊都在嘗試進行一種在100年前就採用的方法來治療和預防新冠肺炎,該療法曾經在1918年的流感大流行期間使用。在感染過程中,人體開始製造攻擊侵入人體的細菌的抗體。這些抗體可以在倖存者的血漿中停留數月或數年。
According to reported that doctors and research teams around the world are trying to use a method that was used during the 1918 flu pandemic to treat and prevent COVID-19.
During the infection, the body begins to produce antibodies designed to attack bacteria that invade the body. These antibodies stay in the plasma of survivors for months or years.
這不是治癒的方法,但是卻是減少疾病嚴重程度的一種方法。目前研究人員還不知道倖存者的抗體能在血漿中保留多長時間。然而,科學家在尋找疫苗或新藥時可以使用這種臨時的治療方法。因為康復患者的血液中充滿了免疫分子,將從康復患者身上取得的血漿抗體注入患病者身上,可以幫助倖存者抵抗COVID-19
This is not a cure, but a way to reduce the severity of the disease. Researchers also don't know how long the survivors' antibodies will remain in the plasma. However, scientists can use this temporary treatment when looking for vaccines or new medicines. The blood from former patients is filled with immune molecules that can help survivors defeat COVID-19, the disease caused by the coronavirus. This means giving blood plasma from recovered patients to sick ones.
中國醫生報導說,有五名接受過康復者血漿治療的人在一周後開始好轉。但是他們還接受了其他治療,因此無法得知是否是因使用血漿而使病情改善。
Chinese doctors reported that five people treated with plasma from former patients all began to improve a week later. But they also received other treatments, so there is no way to know if the plasma by itself caused the improvements.
美國國立衛生研究院的研究人員正在測量倖存者的抗體水平,以了解疫苗的強度。其他科學家,包括北京清華大學的一些科學家,正試圖找出哪種抗體最強。他們希望在實驗室中複製這些抗體並創建藥物治療方法。
Researchers at the National Institute of Health are measuring survivors’ antibody levels to learn how strong a vaccine must be. Other scientists, including some at Beijing’s Tsinghua University, are trying to find out which antibodies are the strongest. They hope to copy those antibodies in a lab and create a drug treatment.
全球有許多康復患者已經同意捐贈血液給當地的醫院或研究機構。
Many rehabilitated patients worldwide have agreed to donate blood to local hospitals or research institutions.
從確認可行到量產需要花費很長的時間,目前全球都還沒有確定的方案可行,為何不試試採用數位製藥的方式。這種技術根本不需要花太多的成本。因為只需要確認該抗體有效,就可以用極少的公克量製作成數位電子藥,個別遠距傳輸到所有病人身上。每日劑量多寡,只需用時間和載體數量控制。一個數位電子疫苗可以全球使用。當病毒株產生變異時,也能在很短的時間裡開發新型疫苗和治療藥物。
It takes a long time from confirmation to mass production. At present, there are no established solution programs in the world that are feasible. Why not try to adopt the method of digital pharmaceuticals? This technology is inexpensive. It only needs to confirm that the antibodies are effective. It can be made into digital electronic medicine and only needs a very small amount of grams of antibodies. It can be transmitted to all patients and there is no distance limit. The daily amount of drugs depends on time and carrier quantity. The digital electronic vaccine can be used globally, and when the virus strain is mutated, new vaccines and therapeutic drugs can also be developed in a short period of time.
不要排斥新的科技防疫技術! 從過去至今,許多研究都曾經跌破無數專家的眼鏡,更何況利用數位製藥遠距傳輸的技術來開發疫苗。屆時,醫護人員完全不需要靠近病人就能為他們傳送疫苗,為何不試試?
Don't exclude the new technology! From the past to the present time, many studies have broken the glasses of countless experts, not to mention the use of digital pharmaceutical long-distance transmission technology to develop vaccines. If successful, at that time, medical staff can deliver vaccines for patients without having to be close to them. Why not try?